Ray, John P.
de Boer, Carl G.
Fulco, Charles P. http://orcid.org/0000-0002-6592-1279
Lareau, Caleb A. http://orcid.org/0000-0003-4179-4807
Kanai, Masahiro http://orcid.org/0000-0001-5165-4408
Ulirsch, Jacob C. http://orcid.org/0000-0002-7947-0827
Tewhey, Ryan http://orcid.org/0000-0002-4607-8001
Ludwig, Leif S.
Reilly, Steven K.
Bergman, Drew T. http://orcid.org/0000-0002-8314-7088
Engreitz, Jesse M. http://orcid.org/0000-0002-5754-1719
Issner, Robbyn
Finucane, Hilary K. http://orcid.org/0000-0003-3864-9828
Lander, Eric S. http://orcid.org/0000-0003-2662-4631
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (P50 HG006193)
Article History
Received: 3 February 2020
Accepted: 17 February 2020
First Online: 6 March 2020
Competing interests
: AR is a co-founder and equity holder of Celsius Therapeutics, a founder of Immunitas, and SAB member of ThermoFisher Scientific, Asimov Neogene Therapeutics, and Syros Pharmaceuticals. NH is a co-founder and equity holder of Neon Therapeutics. ESL serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics, and serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he is also affiliated with several non-profit organizations including serving on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative, and the Board of Trustees for the Parker Institute for Cancer Immunotherapy. ESL has served and continues to serve on various federal advisory committees.